RAPAFLO (Avera McKennan Hospital)
Welcome to the PulseAid listing for the RAPAFLO drug offered from Avera McKennan Hospital. This Adrenergic alpha-Antagonists [MoA],alpha-Adrenergic Blocker [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Avera McKennan Hospital |
NON-PROPRIETARY NAME: | silodosin |
SUBSTANCE NAME: | SILODOSIN |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Adrenergic alpha-Antagonists [MoA],alpha-Adrenergic Blocker [EPC] |
ROUTE: | ORAL |
DOSAGE FORM: | CAPSULE |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2015-03-23 |
END MARKETING DATE: | 0000-00-00 |
RAPAFLO HUMAN PRESCRIPTION DRUG Details:
Item Description | RAPAFLO from Avera McKennan Hospital |
LABELER NAME: | Avera McKennan Hospital |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 8(mg/1) |
START MARKETING DATE: | 2015-03-23 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 69189-0169_e513ac0a-443c-4b0b-a180-5603b7bd4a01 |
PRODUCT NDC: | 69189-0169 |
APPLICATION NUMBER: | NDA022206 |
Other SILODOSIN Pharmaceutical Manufacturers / Labelers: